Visualitzant O - Articles científics per títol

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Bordonaro, R.; Calvo, A.; Auriemma, A.; Hollebecque, Antoine; Rubovszky, G.; Saunders, M. P.; Argilés Martinez, Guillem; Tabernero Caturla, Josep (Elsevier, 2021-10)

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Tabernero Caturla, Josep; Prager, Gerald W; Leger, Catherine; Fakih, Marwan; Taieb, Julien; Ciardiello, Fortunato (Future Medicine, 2021-06)

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Elsevier, 2020-09)

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Tabernero Caturla, Josep; Shitara, Kohei; Zaanan, Aziz; Doi, Toshihiko; Lorenzen, S.; Van Cutsem, Eric; Alsina Maqueda, Maria (Elsevier, 2021-08)

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Napolitano, Stefania; Matrone, Nunzia; Muddassir, A. L.; Martini, Giulia; Sorokin, A.; De Falco, Vincenzo (BMC, 2019-12-16)

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

Tolaney, Sara M; Arteaga, Carlos; Cortés Castan, Javier; Sohn, Joohyuk; Rugo, Hope; Bardia, Aditya (Future Medicine, 2020-04)

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Levy, Benjamin; Cappuzzo, Federico; Yoneshima, Yasuto; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Future Medicine, 2023-07)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

Vieito Villar, Maria; De Vos, Filip; Marjolein Geurts; Lorenzi, Elena; Moreno, Victor; Simonelli, Matteo (Oxford University Press, 2022-01)

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Nagasaka, Misako; Ohe, Yuichiro; Choi, Chang-Min; Yang, Nong; FELIP, ENRIQUETA; Zhou, Caicun; Liu, Geoffrey (Future Medicine, 2023-01)

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Rofes, Paula; Duenas Cid, Nuria; del Valle, Jesús; Navarro, Matilde; Balmaña, Judith; Ramon y Cajal, Teresa (Wiley, 2024-04-01)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Casarrubios García, Marta; Garcia‑Campelo, Rosario; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest; Lázaro, Martín (BMJ, 2022-09)

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Vergote, Ignace; Hirsch, Fred R.; Hagemann, Carsten; Miller, David; Macarulla, Teresa (MDPI, 2023-01-19)

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

Gkika, Eleni; Grosu, Anca; Macarulla Mercade, Teresa; Brunner, Thomas B.; Schultheiß, Michael; Cubillo, Antonio (MDPI, 2022-03-18)

Tumor-Associated Microbiome: Where Do We Stand?

Oliva, Marc; Mulet Margalef, Núria; Ochoa de Olza Amat, Maria; Napoli, Stefania; Mas Lloret, Joan; Laquente, Berta; Nuciforo, Paolo Giovanni (MDPI, 2021-02-01)

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Taraborrelli, Lucia; Şenbabaoğlu, Yasin; Wang, Lifen; Lim, Junghyun; Blake, Kerrigan; Kljavin, Noelyn; Argilés Martinez, Guillem (Springer Nature, 2023-09-23)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Lahiguera, Álvaro; Hyroššová, Petra; Figueras, Agnès; Garzón, Diana; Moreno, Roger; Soto-Cerrato, Vanessa; Serra Elizalde, Violeta (Wiley, 2020-06-08)

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics

Senis Herrero, Elena; Esgleas, Miriam; Najas, Sonia; Jiménez-Sábado, Verónica; Bertani, Camilla; Gimenez Alejandre, Marta; Escriche, Alba; Jimenez, Mireia; Nuciforo, Paolo Giovanni; Abad Mendez, Maria (Frontiers Media, 2021-12)

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Bang, Yung-Jue; Ryu, Min-Hee; FAGNIEZ, Nathalie; Tabernero, Josep; Bedard, Philippe; Vieito , Maria (American Association for Cancer Research, 2023-08)

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

Le Tourneau, Christophe; Becker, Heiko; Claus, Rainer; Ricci, Francesco; Fritsch, R.; Elez, Elena; Tabernero, Josep (Elsevier, 2022-10)

UNCAN.eu: Toward a European Federated Cancer Research Data Hub

Boutros, Michael; Baumann, Michael; Bigas, Anna; Chaabane, Linda; Guérin, Julien; Habermann, Jens; Tabernero, Josep (American Association for Cancer Research, 2024-01-01)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

Tumor-Associated Microbiome: Where Do We Stand?

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

UNCAN.eu: Toward a European Federated Cancer Research Data Hub

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study ﻿

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design ﻿

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study ﻿

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study ﻿

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression ﻿

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer ﻿

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC ﻿

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma ﻿

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors ﻿

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation ﻿

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy ﻿

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment ﻿

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study ﻿

Tumor-Associated Microbiome: Where Do We Stand? ﻿

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer ﻿

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors ﻿

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics ﻿

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens ﻿

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors ﻿

UNCAN.eu: Toward a European Federated Cancer Research Data Hub ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study

Tumor-Associated Microbiome: Where Do We Stand?

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

UNCAN.eu: Toward a European Federated Cancer Research Data Hub